1. Treatment of intracranial human glioblastoma by direct intratumoral administration of 'III-labelled anti-tenascin monoclonal antibody BC-2;Riva, P.; Arista, A.; Sturiale, C.; Moscatelli, G.; Tison, V.; Mariani, M.;Int J Cancer,1992
2. Radioimmunotherapy of CNS malignant gliomas by direct intralesional injection of specific ''I radio-labelled monoclonal antibodies;Riva, P.; Arista, A.; Sturiale, C.; Tison, V.; Fratterelli, M.; Lazzari, S.;Cancer,1994
3. Tenascin distribution in human brain tumours;Castellani, P.; Dorcaratto, A.; Siri, A.; Zardi, L.; Viale, G.L.;Acta Neurochir (Wien),1995
4. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin;Balza, E.; Siri, A.; Ponassi, M.; Caocci, F.; Linnala, A.; Virtanen, I.; Zardi, L.;FEBS,1994
5. Pre-targeting immunodetection in glioma patient: tumor localization and SPECT immaging of [Tc99m] PnAO biotin;Paganelli, G.; Magnani, F.; Zito, F.; Lucignani, G.; Sudati, F.; Truci, G.;J Nucl Med,1994